Comparative evaluation of cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH

Nabil Abd Elhamid Omar; Hassan Elsayed Zaghla; Ahmed Mohamed Omara; Talaat Zakareya Ibrahim; Esam Mohamed Zayed; Walaa Khairy Abdelbadie

doi:10.53730/ijhs.v6nS10.13568

Authors

Nabil Abd Elhamid Omar Professor of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Egypt
Hassan Elsayed Zaghla Professor of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Egypt
Ahmed Mohamed Omara Professor of Cardiology, Menofia University, Egypt
Talaat Zakareya Ibrahim Associated professor of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Egypt
Esam Mohamed Zayed Fellow of Hepatology, National Liver Institute, Menofia University, Egypt
Walaa Khairy Abdelbadie
noursalmahany@gmail.com
M.B., B.Ch, MSc Hepatology, Mataria Teaching Hospital, Egypt

Keywords:

cardiac health, chronic liver disease, cirrhosis

Abstract

Background: There is a documented relationship between chronic liver disease and cardiac dysfunction. The current investigation aims to compare the cardiac health in patients with chronic liver disease secondary to HCV, HBV, and NASH. Patients and Methods: This prospective study included 150 patients divided into three groups; Group I (50 HCV cases), Group II (50 HBV cases), and Group III (50 NASH cases). Each group was subdivided into two equal subgroups; the A subgroup included patients without liver cirrhosis, and the B subgroup included patients with liver cirrhosis. The assessment included laboratory biomarkers, transabdominal ultrasound, fibroscan, echocardiography, and carotid doppler. Results: EF had mean values of 62.58, 62.8, and 64.14%, whereas prolonged QT interval was noted in 30%, 40%, and 37% of patients in the three groups, respectively. E/A ratios > 1 were detected in 70%, 66%, and 72% of patients, while carotid atherosclerosis was detected in 28%, 28%, and 32% in the same three groups, respectively. All of the previous parameters were comparable between the three main groups. On comparing subgroups A to B, prolonged QT intervals, carotid atherosclerosis, and decreased EF were more noticed in the latter.

Downloads

Download data is not yet available.

References

Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H, et al. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep. 2021;11(1):15938.https://doi.org/10.1038/s41598-021-95581-8.

Barakat AAE-K, Nasr FM, Metwaly AA, Morsy S, Eldamarawy M. Atherosclerosis in chronic hepatitis C virus patients with and without liver cirrhosis. The Egyptian Heart Journal. 2017;69(2):139-47.https://doi.org/https://doi.org/10.1016/j.ehj.2016.10.004.

Baratta F, D'Erasmo L, Bini S, Pastori D, Angelico F, Del Ben M, et al. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis. 2022;357:51-9.https://doi.org/10.1016/j.atherosclerosis.2022.08.011.

Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahlström U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004;6(4):453-61.https://doi.org/10.1016/j.ejheart.2004.02.003.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48.https://doi.org/10.1016/j.metabol.2015.12.012.

Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022;24 Suppl 2:28-43.https://doi.org/10.1111/dom.14484.

Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. Bmj. 2000;321(7255):215-8.https://doi.org/10.1136/bmj.321.7255.215.

Chen C, Zhu Z, Mao Y, Xu Y, Du J, Tang X, et al. HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. Biosci Rep. 2020;40(1).https://doi.org/10.1042/bsr20193996.

Demir M, Demir C. Effect of hepatitis B virus infection on right and left ventricular functions. Med Sci Monit. 2012;18(9):Cr587-91.https://doi.org/10.12659/msm.883356.

Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36(5):621-7.https://doi.org/10.1111/liv.13064.

Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest. 2021;51(7):e13519.https://doi.org/10.1111/eci.13519.

Enany B, El Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz. 2012;37(5):527-33.https://doi.org/10.1007/s00059-011-3547-z.

Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci. 1998;43(8):1701-7.https://doi.org/10.1023/a:1018867232562.

Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, Pieruzzi F, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond). 2009;116(12):851-9.https://doi.org/10.1042/cs20080325.

Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;22(3):326-32.https://doi.org/10.1016/0168-8278(95)80286-x.

Kablak-Ziembicka A, Tracz W, Przewlocki T, Pieniazek P, Sokolowski A, Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart. 2004;90(11):1286-90.https://doi.org/10.1136/hrt.2003.025080.

Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol. 1984;54(7):852-5.https://doi.org/10.1016/s0002-9149(84)80220-9.

Kelbaek H, Rabøl A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, et al. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin Physiol. 1987;7(1):35-41.https://doi.org/10.1111/j.1475-097x.1987.tb00631.x.

Keller H, Bezjak V, Stegaru B, Buss J, Holm E, Heene DL. Ventricular function in cirrhosis and portasystemic shunt: a two-dimensional echocardiographic study. Hepatology. 1988;8(3):658-62.https://doi.org/10.1002/hep.1840080337.

Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8(1):1661.https://doi.org/10.1038/s41598-017-17936-4.

Li L, Liu HR, Shu JL, Xi XP, Wang Y. [Clinical investigation of Q-T prolongation in hepatic cirrhosis]. Zhonghua Yi Xue Za Zhi. 2007;87(38):2717-8

Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? World J Clin Cases. 2021;9(31):9320-32.https://doi.org/10.12998/wjcc.v9.i31.9320.

Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol. 2021;18(2):117-35.https://doi.org/10.1038/s41569-020-0433-5.

Mishra S, Yadav D, Gupta M, Mishra H, Sharma P. A Study of Carotid Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease. Indian J Clin Biochem. 2013;28(1):79-83.https://doi.org/10.1007/s12291-012-0286-8.

Moaref A, Zamirian M, Yazdani M, Salehi O, Sayadi M, Aghasadeghi K. The Correlation between Echocardiographic Findings and QT Interval in Cirrhotic Patients. Int Cardiovasc Res J. 2014;8(2):39-43

Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut. 2008;57(2):268-78.https://doi.org/10.1136/gut.2006.112177.

Nasr FM, Metwaly A, Khalik AA, Darwish H. Cardiac dysfunction in liver cirrhosis: A tissue Doppler imaging study from Egypt. Electron Physician. 2015;7(4):1135-43.https://doi.org/10.14661/2015.1135-1143.

Ogawa Y, Imajo K, Yoneda M, Nakajima A. [Pathophysiology of NAsh/NAFLD associated with high levels of serum triglycerides]. Nihon Rinsho. 2013;71(9):1623-9

Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258-67.https://doi.org/10.1016/j.atherosclerosis.2013.07.052.

Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res. 2017;8(2):161-8.https://doi.org/10.1016/j.jare.2016.06.001.

Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26(5):1131-7.https://doi.org/10.1002/hep.510260507.

Sia CH, Ngiam JN, Chew N, Beh DLL, Poh KK. Educational case series of electrocardiographs during the COVID-19 pandemic and the implications for therapy. Singapore Med J. 2020;61(8):406-12.https://doi.org/10.11622/smedj.2020087.

Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49(4):600-7.https://doi.org/10.1016/j.jhep.2008.06.012.

Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med. 2021;9(8):729.https://doi.org/10.21037/atm-20-4354.

Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17).https://doi.org/10.3390/ijerph16173104.

Țieranu E, Donoiu I, Istrătoaie O, Găman AE, Țieranu LM, Gheonea DI, et al. Q-T Interval Prolongation in Patients with Liver Cirrhosis. Curr Health Sci J. 2018;44(3):274-9.https://doi.org/10.12865/chsj.44.03.11.

Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49(2):268-75.https://doi.org/10.1136/gut.49.2.268.

Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond). 1999;97(3):259-67

Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009;3(1):294-304.https://doi.org/10.1007/s12072-008-9109-7.

Yuan W, Lu HZ, Mei X, Zhang YY, Zhang ZG, Zou Y, et al. Cardiac health in patients with hepatitis B virus-related cirrhosis. Medicine (Baltimore). 2019;98(13):e14961.https://doi.org/10.1097/md.0000000000014961.